Tweetable abstract Severe COVID-19 patients display dysregulated expression of checkpoint molecules PD-1 and its ligand PD-L1, suggesting that these checkpoint molecules could be considered as prognostic markers and therapeutic targets in severe cases of COVID-19.
Keywords: COVID-19; PD-1; PD-L1; SARS-CoV-2; adaptive immune cells; immune checkpoint molecules; innate immune cells.